Figure 1
Univariate analyses of overall survival (OS); p-values were received from the Wilcoxon test_
| Characteristic | OS at 3 months (%) | OS at 6 months (%) | OS at 9 months (%) | OS at 12 months (%) | P-value |
|---|---|---|---|---|---|
| Age | |||||
| ≤61 years | 58 | 39 | 30 | 24 | |
| ≥62 years | 47 | 28 | 22 | 15 | 0.076 |
| Karnofsky performance score | |||||
| <70% | 26 | 8 | 5 | ||
| 70% | 54 | 32 | 19 | ||
| >70% | 89 | 72 | 60 | 51 | <0.001 |
| Time between first diagnosis of breast cancer | |||||
| and WBRT | |||||
| ≤33 months | 46 | 29 | 22 | 18 | |
| ≥34 months | 59 | 38 | 29 | 21 | 0.062 |
| Systemic treatment prior to WBRT | |||||
| No | 45 | 23 | 11 | 11 | |
| Yes | 53 | 35 | 28 | 21 | 0.27 |
| Number of cerebral lesions | |||||
| 1-3 | 46 | 35 | 27 | 18 | |
| ≥4 | 55 | 33 | 36 | 20 | 0.43 |
| Controlled primary tumor | |||||
| No | 33 | 25 | 25 | 25 | |
| Yes | 54 | 34 | 26 | 19 | 0.18 |
| Extra-cerebral metastatic disease | |||||
| No | 76 | 53 | 43 | 36 | |
| Yes | 45 | 28 | 21 | 15 | 0.001 |
| Entire cohort | 52 | 34 | 26 | 20 |
Distribution of the patient characteristics
| Characteristic | Number of patients | Proportion (%) |
|---|---|---|
| Age | ||
| ≤61 years | 85 | 50 |
| ≥62 years | 85 | 50 |
| Karnofsky performance score | ||
| <70% | 76 | 45 |
| 70% | 41 | 24 |
| >70% | 53 | 31 |
| Time between first diagnosis of breast cancer and | ||
| WBRT | ||
| ≤33 months | 85 | 50 |
| ≥34 months | 85 | 50 |
| Systemic treatment prior to WBRT | ||
| No | 22 | 13 |
| Yes | 148 | 87 |
| Number of cerebral lesions | ||
| 1-3 | 52 | 31 |
| ≥4 | 118 | 69 |
| Controlled primary tumor | ||
| No | 12 | 7 |
| Yes | 158 | 93 |
| Extra-cerebral metastatic disease | ||
| No | 38 | 22 |
| Yes | 132 | 78 |
Six-month overall survival rates (OS) of the characteristics included in the WBRT-30-BC and the related scoring points
| Characteristic | 6-month OS rate (%) | Scoring points |
|---|---|---|
| Karnofsky performance score | ||
| <70% | 8 | 1 |
| 70% | 32 | 3 |
| >70% | 72 | 7 |
| Time between first diagnosis of breast cancer and WBRT | ||
| ≤33 months | 29 | 3 |
| ≥34 months | 38 | 4 |
| Extra-cerebral metastatic disease | ||
| No | 53 | 5 |
| Yes | 28 | 3 |
Overall survival (OS) rates of the four prognostic groups at 3, 6, 9 and 12 months following WBRT; the p-value was received from the Wilcoxon test
| Prognostic group | OS at 3 months (%) | OS at 6 months (%) | OS at 9 months (%) | OS at 12 months (%) | P-value |
|---|---|---|---|---|---|
| 6-9 points | 25 | 8 | 5 | 2 | |
| 10-12 points | 69 | 41 | 25 | 0 | |
| 13-15 points | 87 | 68 | 54 | 47 | |
| 16 points | 100 | 100 | 100 | 83 | <0.001 |